Clinical Trials Logo

Clinical Trial Summary

It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.


Clinical Trial Description

After providing written informed consent, all patients will be randomized to receive ticagrelor 360mg or 180mg loading dose(LD),then 90mg bid maintenance dose starting 12 hours after LD.PCI will performed in 2h-72h after they are given the loading dose.All patients should receive acetylsalicylic acid (ASA) 75 to 100 mg daily unless intolerant.IPA at 0, 0.5, 1, 2, 8, 24h after the loading dose of ticagrelor will be measured. CK-MB, troponin I, myoglobin, CRP will be detected at 0h, before PCI, 8h after PCI, 24h after PCI. ECG will be conducted at 0h and within 24h after PCI. Patients returned 28 days for follow-up visits after the loading dose of ticagrelor, documented any adverse events. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01962428
Study type Interventional
Source General Hospital of Chinese Armed Police Forces
Contact
Status Completed
Phase Phase 4
Start date June 2014
Completion date October 2015

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Recruiting NCT05117866 - Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study N/A
Recruiting NCT02578537 - COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS Phase 4
Recruiting NCT06051110 - Individual Patient Data Meta-analysis on Prehospital Risk Assessment in Patients Suspected of Non-ST-segment Elevation Acute Coronary Syndrome N/A
Withdrawn NCT03300167 - Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling N/A
Terminated NCT02071966 - Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS Phase 4
Not yet recruiting NCT06096909 - Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population N/A
Recruiting NCT05125276 - Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients Phase 4
Recruiting NCT03863327 - EKG Criteria and Identification of Acute Coronary Occlusion
Completed NCT04400500 - Differential Diagnosis and Risk Stratification in Patients With Suspected NSTEACS
Recruiting NCT04476173 - ANalgesic Efficacy and Safety of MOrphiNe Versus Methoxyflurane in Patients With Acute Myocardial Infarction Phase 3
Recruiting NCT06255678 - Angio-based Final Functional Effect of PCI
Not yet recruiting NCT06197724 - MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients
Recruiting NCT05250596 - COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS) Phase 2
Completed NCT02073565 - HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt N/A
Completed NCT04766437 - Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy Phase 2
Not yet recruiting NCT05202041 - Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS N/A
Recruiting NCT02415803 - Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS Phase 3
Not yet recruiting NCT05779059 - Prasugrel Or Ticagrelor De-escalation in NSTE-ACS Phase 3